WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, May 05, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L6	exendin$ same ((pharmaceutic$ or therapeutic$) same (composition? or fomulat$)) and (m-cresol or 3-methylphenol)	2
☐	L5	exendin$ same ((pharmaceutic$ or therapeutic$) same (composition? or fomulat$)) and (buffer? and (iso$osmola$ or isotonic$)) and (preservative? or m-cresol or 3-methylphenol)	4
☐	L4	exendin$ same ((pharmaceutic$ or therapeutic$) same (composition? or fomulat$)) and (buffer? and (iso$osmola$ or isotonic$)) and (preservative? or $cresol)	4
☐	L3	exendin$ same ((pharmaceutic$ or therapeutic$) same (composition? or fomulat$)) and (buffer? and (iso$osmola$ or isotonic$)) and (non-ion$ same detergent? or surfactant?)	1
☐	L2	exendin$ same ((pharmaceutic$ or therapeutic$) same (composition? or fomulat$)) and (buffer? and (iso$osmola$ or isotonic$))	10
☐	L1	(pharmaceutic$ or therapeutic$) same (composition? or fomulat$) same exendin$ same (buffer? and (iso$osmola$ or isotonic$))	2

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20030087820 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 2 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087820
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087820 A1

TITLE: Novel exendin agonist formulations and methods of administration thereof

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Andrew A.	La Jolla	CA	US	
Kolterman, Orville G.	Poway	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20030036504 A1

L6: Entry 2 of 2 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036504
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036504 A1

TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kolterman, Orville G.	Poway	CA	US	
Young, Andrew A.	Point Loma	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents
M-CRESOL	8692
M-CRESOLS	44
3-METHYLPHENOL	365
3-METHYLPHENOLS	2
EXENDIN$	0
EXENDIN	284
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
(EXENDIN$ SAME ((PHARMACEUTIC$ OR THERAPEUTIC$) SAME (COMPOSITION? OR FOMULAT$)) AND (M-CRESOL OR 3-METHYLPHENOL)).PGPB,USPT,EPAB,DWPI,TDBD.	2

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20030087820 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 4 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087820
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087820 A1

TITLE: Novel exendin agonist formulations and methods of administration thereof

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Andrew A.	La Jolla	CA	US	
Kolterman, Orville G.	Poway	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20030036504 A1

L4: Entry 2 of 4 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036504
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036504 A1

TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kolterman, Orville G.	Poway	CA	US	
Young, Andrew A.	Point Loma	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 6602694 B1

L4: Entry 3 of 4 File: USPT Aug 5, 2003

US-PAT-NO: 6602694
DOCUMENT-IDENTIFIER: US 6602694 B1

TITLE: Uncoupling protein 4 (UCP-4)

DATE-ISSUED: August 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Albrandt; Keith	San Diego	CA		
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 435/183; 530/333, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 4. Document ID: US 6528486 B1

L4: Entry 4 of 4 File: USPT Mar 4, 2003

US-PAT-NO: 6528486
DOCUMENT-IDENTIFIER: US 6528486 B1

TITLE: Peptide agonists of GLP-1 activity

DATE-ISSUED: March 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Bjarne Due	Br.o slashed.nsh.o slashed.j			DK
Mikkelsen; Jens Damsgaard	Lyngby			DK
Neve; S.o slashed.ren	Lyngby			DK

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/303

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents

EXENDIN$	0
EXENDIN	286
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
EXENDIN4	11
EXENDIN-AGONIST	1
EXENDIN-ANALOGS	1
EXENDIN-ENCODING	1
(EXENDIN$ SAME ((PHARMACEUTIC$ OR THERAPEUTIC$) SAME (COMPOSITION? OR FOMULAT$)) AND (BUFFER? AND (ISO$OSMOLA$ OR ISOTONIC$)) AND (PRESERVATIVE? OR $CRESOL)).PGPB,USPT,EPAB,DWPI,TDBD.	4

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6528486 B1

Using default format because multiple data bases are involved.

L3: Entry 1 of 1 File: USPT Mar 4, 2003

US-PAT-NO: 6528486
DOCUMENT-IDENTIFIER: US 6528486 B1

TITLE: Peptide agonists of GLP-1 activity

DATE-ISSUED: March 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Bjarne Due	Br.o slashed.nsh.o slashed.j			DK
Mikkelsen; Jens Damsgaard	Lyngby			DK
Neve; S.o slashed.ren	Lyngby			DK

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/303

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents
EXENDIN$	0
EXENDIN	286
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
EXENDIN4	11
EXENDIN-AGONIST	1
EXENDIN-ANALOGS	1
EXENDIN-ENCODING	1
(EXENDIN$ SAME ((PHARMACEUTIC$ OR THERAPEUTIC$) SAME	

(COMPOSITION? OR FOMULAT$)) AND (BUFFER? AND (ISO$OSMOLA$ OR ISOTONIC$)) AND (NON-ION$ SAME DETERGENT? OR SURFACTANT?)).PGPB,USPT,EPAB,DWPI,TDBD.	1

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 20040023871 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 10 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023871
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023871 A1

TITLE: Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hiles, Richard A.	San Diego	CA	US	
Prickett, Kathryn S.	San Diego	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20030087821 A1

L2: Entry 2 of 10 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087821
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087821 A1

TITLE: Exendins, exendin agonists, and methods for their use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Beeley, Nigel Robert Arnold	Solana Beach	CA	US	
Prickett, Kathryn S.	San Diego	CA	US	
Bhavsar, Sunil	San Diego	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 20030087820 A1

L2: Entry 3 of 10 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087820
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087820 A1

TITLE: Novel exendin agonist formulations and methods of administration thereof

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Andrew A.	La Jolla	CA	US	
Kolterman, Orville G.	Poway	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 4. Document ID: US 20030036504 A1

L2: Entry 4 of 10 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036504
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036504 A1

TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kolterman, Orville G.	Poway	CA	US	
Young, Andrew A.	Point Loma	CA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 5. Document ID: US 20020141985 A1

L2: Entry 5 of 10 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020141985
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020141985 A1

TITLE: Peptide YY and peptide YY agonists for treatment of metabolic disorders

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pittner, Richard A.	San Diego	CA	US	
Young, Andrew A.	La Jolla	CA	US	
Paterniti, James R. JR.	San Diego	CA	US	

US-CL-CURRENT: 424/94.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 20020137666 A1

L2: Entry 6 of 10 File: PGPB Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137666
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020137666 A1

TITLE: USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BEELEY, NIGEL ROBERT ARNOLD	SOLANA BEACH	CA	US	
PRICKETT, KATHRYN S.	SAN DIEGO	CA	US	
BHAVSAR, SUNIL	SAN DIEGO	CA	US	

US-CL-CURRENT: 514/2; 514/12, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 6703359 B1

L2: Entry 7 of 10 File: USPT Mar 9, 2004

US-PAT-NO: 6703359
DOCUMENT-IDENTIFIER: US 6703359 B1

TITLE: Inotropic and diuretic effects of exendin and GLP-1

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Vine; Will	Poway	CA		
Beeley; Nigel R. A.	Solana Beach	CA		
Prickett; Kathryn	San Diego	CA		

US-CL-CURRENT: 514/2; 514/866, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | [illegible] | [illegible] | Claims | KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 6602694 B1

L2: Entry 8 of 10 File: USPT Aug 5, 2003

US-PAT-NO: 6602694
DOCUMENT-IDENTIFIER: US 6602694 B1

TITLE: Uncoupling protein 4 (UCP-4)

DATE-ISSUED: August 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Albrandt; Keith	San Diego	CA		
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 435/183; 530/333, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | [illegible] | [illegible] | Claims | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 6528486 B1

L2: Entry 9 of 10 File: USPT Mar 4, 2003

US-PAT-NO: 6528486
DOCUMENT-IDENTIFIER: US 6528486 B1

TITLE: Peptide agonists of GLP-1 activity

DATE-ISSUED: March 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Bjarne Due	Br.o slashed.nsh.o slashed.j			DK
Mikkelsen; Jens Damsgaard	Lyngby			DK
Neve; S.o slashed.ren	Lyngby			DK

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/303

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 10. Document ID: US 6506724 B1

L2: Entry 10 of 10 File: USPT Jan 14, 2003

US-PAT-NO: 6506724
DOCUMENT-IDENTIFIER: US 6506724 B1

TITLE: Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hiles; Richard A.	San Diego	CA		
Prickett; Kathryn S.	San Diego	CA		

US-CL-CURRENT: 514/2; 514/12, 514/3, 514/4, 514/866, 530/300, 530/324, 530/325

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents
EXENDIN$	0
EXENDIN	286
EXENDINE	2
EXENDINES	1
EXENDING	612
EXENDING-4	1
EXENDINS	45
EXENDIN4	11
EXENDIN-AGONIST	1
EXENDIN-ANALOGS	1
EXENDIN-ENCODING	1
(EXENDIN$ SAME ((PHARMACEUTIC$ OR THERAPEUTIC$) SAME (COMPOSITION? OR FOMULAT$)) AND (BUFFER? AND (ISO$OSMOLA$ OR ISOTONIC$))).PGPB,USPT,EPAB,DWPI,TDBD.	10

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page Go to Doc#

FILE 'HOME' ENTERED AT 12:18:31 ON 05 MAY 2004

=> file bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'ANABSTR' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'CAPLUS' ENTERED AT 12:19:18 ON 05 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:19:18 ON 05 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'FOMAD' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'HEALSAFE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:19:18 ON 05 MAY 2004

FILE 'NIOSHTIC' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:19:18 ON 05 MAY 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:19:18 ON 05 MAY 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:19:18 ON 05 MAY 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:19:18 ON 05 MAY 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 ACS

```
FILE 'USPATFULL' ENTERED AT 12:19:18 ON 05 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:19:18 ON 05 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 American Society of Hospital Pharmacists (ASHP)

FILE 'NAPRALERT' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 12:19:18 ON 05 MAY 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

=> s exendin? (s)((pharmaceutic? or therapeutic?) (s) (composition# or fomulat?)) and
(buffer and (iso?osmola? or isotonic?)) and (preservative or m-cresol or 3 (w)
methylphenol)
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'ISO?OSMOLA?'
The truncation symbol ?  may be used only at the end of a search
term.  To specify a variable character within a word use '!', e.g.,
'wom!n' to search for both 'woman' and 'women'.  Enter "HELP
TRUNCATION" at an arrow prompt (=>) for more information.

=> s exendin? (s)((pharmaceutic? or therapeutic?) (s) (composition# or fomulat?)) and
(buffer and (?osmola? or isotonic?))and (preservative or m-cresol or 3 (w) methylphenol)
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ADISCTI'
L1            0 FILE ADISCTI
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ADISINSIGHT'
L2            0 FILE ADISINSIGHT
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ADISNEWS'
L3            0 FILE ADISNEWS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'AGRICOLA'
L4            0 FILE AGRICOLA
L5            0 FILE ANABSTR
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'AQUASCI'
L6            0 FILE AQUASCI
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'BIOBUSINESS'
L7            0 FILE BIOBUSINESS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'BIOCOMMERCE'
L8            0 FILE BIOCOMMERCE
L9            0 FILE BIOSIS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'BIOTECHDS'
L10           0 FILE BIOTECHDS
L11           0 FILE BIOTECHNO
L12           0 FILE CABA
L13           0 FILE CANCERLIT
L14           0 FILE CAPLUS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CEABA-VTB'
L15           0 FILE CEABA-VTB
```

```
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CEN'
L16           0 FILE CEN
L17           0 FILE CIN
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CONFSCI'
L18           0 FILE CONFSCI
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CROPB'
L19           0 FILE CROPB
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'CROPU'
L20           0 FILE CROPU
L21           0 FILE DISSABS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DGENE'
L22           0 FILE DGENE
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DRUGB'
L23           0 FILE DRUGB
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DRUGMONOG2'
L24           0 FILE DRUGMONOG2
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IMSDRUGNEWS'
L25           0 FILE IMSDRUGNEWS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'DRUGU'
L26           0 FILE DRUGU
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IMSRESEARCH'
L27           0 FILE IMSRESEARCH
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'EMBAL'
L28           0 FILE EMBAL
L29           0 FILE EMBASE
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'ESBIOBASE'
L30           0 FILE ESBIOBASE
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'FEDRIP'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'APEUTIC?) (S) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN? (S)('
L31           0 FILE FEDRIP
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'FOMAD'
L32           0 FILE FOMAD
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'FOREGE'
L33           0 FILE FOREGE
L34           0 FILE FROSTI
L35           0 FILE FSTA
L36           0 FILE GENBANK
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'HEALSAFE'
L37           0 FILE HEALSAFE
L38           0 FILE IFIPAT
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IMSPRODUCT'
L39           0 FILE IMSPRODUCT
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'JICST-EPLUS'
L40           0 FILE JICST-EPLUS
L41           0 FILE KOSMET
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'LIFESCI'
L42           0 FILE LIFESCI
L43           0 FILE MEDICONF
L44           0 FILE MEDLINE
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'NIOSHTIC'
L45           0 FILE NIOSHTIC
L46           0 FILE NTIS
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'NUTRACEUT'
L47           0 FILE NUTRACEUT
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'OCEAN'
L48           0 FILE OCEAN
L49           0 FILE PASCAL
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'PCTGEN'
L50           0 FILE PCTGEN
L51           0 FILE PHAR
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'PHARMAML'
L52           0 FILE PHARMAML
L53           0 FILE PHIC
```

```
L54           0 FILE PHIN
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'PROMT'
L55           0 FILE PROMT
L56           0 FILE RDISCLOSURE
L57           0 FILE SCISEARCH
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'SYNTHLINE'
L58           0 FILE SYNTHLINE
L59           0 FILE TOXCENTER
L60           5 FILE USPATFULL
L61           0 FILE USPAT2
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'VETB'
L62           0 FILE VETB
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'VETU'
L63           0 FILE VETU
L64           3 FILE WPIDS
L65           0 FILE WPIFV
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'IPA'
L66           0 FILE IPA
L67           0 FILE NAPRALERT
LEFT TRUNCATION IGNORED FOR '?OSMOLA?' FOR FILE 'NLDB'
L68           0 FILE NLDB

TOTAL FOR ALL FILES
L69           8 EXENDIN? (S)((PHARMACEUTIC? OR THERAPEUTIC?) (S) (COMPOSITION#
                OR FOMULAT?)) AND (BUFFER AND (?OSMOLA? OR ISOTONIC?)) AND (PRES
                ERVATIVE OR M-CRESOL OR 3 (W) METHYLPHENOL)
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> d l69 1-8 ibib abs

L69  ANSWER 1 OF 8  USPATFULL on STN
ACCESSION NUMBER:         2003:209956  USPATFULL
TITLE:                    Uncoupling protein 4 (UCP-4)
INVENTOR(S):              Albrandt, Keith, San Diego, CA, United States
                          Beaumont, Kevin, San Diego, CA, United States
                          Young, Andrew A., San Diego, CA, United States
PATENT ASSIGNEE(S):       Amylin Pharmaceuticals, Inc, San Diego, CA, United
                          States (U.S. corporation)

                               NUMBER        KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 6602694         B1   20030805
                          WO 2000004037           20000127
APPLICATION INFO.:        US 2001-743847          20010627  (9)
                          WO 1999-US15861         19990713

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 1998-92737P     19980714 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             GRANTED
PRIMARY EXAMINER:         Eyler, Yvonne
ASSISTANT EXAMINER:       Li, Ruixiang
NUMBER OF CLAIMS:         5
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT:               2275
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel uncoupling protein, which we have designated UCP-4, that is expressed in various tissues, including brain, heart, pancreas, and muscle tissue, and nucleic acid molecules which encode for said novel protein, are described. Methods of screening for compounds that regulate the expression and the activity of UCP-4 are described, as well as methods of treating diseases or conditions in which the regulation of thermogenesis or respiratory ATP synthesis is desired. Such conditions include obesity, diabetes, malignant hyperthermia, and fever. The construction of cell lines that express UCP-4 is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 2 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:127605 USPATFULL

TITLE: Novel exendin agonist formulations and methods of administration thereof

INVENTOR(S): Young, Andrew A., La Jolla, CA, UNITED STATES
Kolterman, Orville G., Poway, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087820	A1	20030508
APPLICATION INFO.:	US 2002-157224	A1	20020528 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-889330, filed on 27 Dec 2001, PENDING A 371 of International Ser. No. WO 2000-US902, filed on 14 Jan 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-116380P	19990114 (60)
	US 2000-175365P	20000110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Molly A. Holman, Ph.D., Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, San Diego, CA, 92121
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 3512

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:60207 USPATFULL

TITLE: Peptide agonists of GLP-1 activity

INVENTOR(S): Larsen, Bjarne Due, Br.o slashed.nsh.o slashed.j, DENMARK
Mikkelsen, Jens Damsgaard, Lyngby, DENMARK
Neve, S.o slashed.ren, Lyngby, DENMARK

PATENT ASSIGNEE(S): Zealand Pharma A/S, Glostrup, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6528486	B1	20030304
APPLICATION INFO.:	US 2000-614847		20000712 (9)

	NUMBER	DATE

PRIORITY INFORMATION: US 1999-143591P 19990712 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: Jiang, Dong
LEGAL REPRESENTATIVE: Buchanan, Robert L., Edwards & Angell, LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 3573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 4 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:51546 USPATFULL
TITLE: Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
INVENTOR(S): Kolterman, Orville G., Poway, CA, UNITED STATES
Young, Andrew A., Point Loma, CA, UNITED STATES
PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003036504	A1	20030220
APPLICATION INFO.:	US 2001-756690	A1	20010109 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175365P	20000110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROBECK, PHLEGER & HARRISON LLP, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for modulating the levels of plasma triglyceride and other lipids in a subject which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood triglyceride and/or other lipid levels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 5 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2001:218592 USPATFULL
TITLE: Extendin derivatives
INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, Denmark
Huusfeldt, Per Olaf, Copenhagen K, Denmark
Nielsen, Per Franklin, Vaerlose, Denmark
Madsen, Kjeld, Vaerlose, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001047084	A1	20011129
APPLICATION INFO.:	US 2001-886311	A1	20010621 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-312177, filed on 14 May 1999, ABANDONED Continuation of Ser. No. WO 1999-DK86, filed on 24 Feb 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1998-274	19980227
	US 1998-84357P	19980505 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401
NUMBER OF CLAIMS: 91
EXEMPLARY CLAIM: 1
LINE COUNT: 2488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a derivative of GLP-1 (7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L69 ANSWER 6 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: 2004-022543 [02] WPIDS
DOC. NO. CPI: C2004-007005
TITLE: Use of a glucagon like peptide-1 agonist or its salt for the preparation of a pharmaceutical composition for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient.
DERWENT CLASS: B04
INVENTOR(S): CARR, R D; CHRISTOFFERSEN, C; ELBROND, B; KNUDSEN, L B; LARSEN, J; NIELSEN, L B; ROLIN, B C; SELMER, J
PATENT ASSIGNEE(S): (CARR-I) CARR R D; (CHRI-I) CHRISTOFFERSEN C; (ELBR-I) ELBROND B; (KNUD-I) KNUDSEN L B; (LARS-I) LARSEN J; (NIEL-I) NIELSEN L B; (ROLI-I) ROLIN B C; (SELM-I) SELMER J; (NOVO) NOVO NORDISK AS
COUNTRY COUNT: 103
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003084563	A1	20031016	(200402)*	EN	14
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
US 2003220255	A1	20031127	(200402)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003084563	A1	WO 2003-DK216	20030402
US 2003220255	A1 Provisional	US 2002-375255P	20020423
		US 2003-406426	20030403

PRIORITY APPLN. INFO: US 2002-375255P 20020423; DK 2002-499 20020404; US 2003-406426 20030403
AN 2004-022543 [02] WPIDS
AB WO2003084563 A UPAB: 20040107
NOVELTY - In the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient a glucagon like peptide-1 (GLP1) agonist or its salt is used.

ACTIVITY - Cardiant; Cardiovascular-Gen.; Antiarrhythmic; Antianginal; Antiarteriosclerotic; Vasotropic; Hypotensive.

MECHANISM OF ACTION - Glucose metabolism regulator; Cardiovascular hemodynamics regulator; Brain natriuretic peptide (BNP) in plasma and/or heart tissue inhibitor. Hearts from 12 streptozotocin (STZ)-treated pigs were collected. The pigs were treated with STZ 2 weeks prior to dosing with either the GLP-1 derivative, Arg34, Lys26(N- eta (gamma -Glu(N-alpha -hexadecanoyl)))-GLP-1(7-37) (NN2211) for 4 weeks, at a dose of 3.3 micro g/kg, subcutaneously once daily or with a vehicle. STZ-treated pigs were either hyperglycemic or glucose intolerant and had impaired insulin secretion upon oral glucose tolerance tests. BNP mRNA and protein levels in cardiac biopsies were measured with real-time PCR and RIA assays, respectively. BNP mRNA levels were normalized by beta -actin mRNA levels. BNP mRNA levels were similar in right atrial (RA), left atrial (LA) and in left ventricular (LV) biopsies from vehicle treated diabetic pigs (-GLP). However, in hearts from NN2211 (+GLP) treated pigs the levels of BNP were significantly lower than in vehicle treated pigs. The BNP mRNAs (arb.units) in the RA, LA and LV in the NN2211/vehicle treated pigs was found to be 0.13/1.3, 0.37/1.5 and 0.75/1.15, respectively.

USE - For the treatment or prevention of an early cardiac or early cardiovascular disease (e.g. left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, atherosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (e.g. atherosclerosis obliterens), diastolic dysfunction and systolic dysfunction) in a diabetic or non-diabetic patient; for the preparation of a pharmaceutical composition for reducing the level of brain natriuretic peptide (BNP) in plasma and/or heart tissue in a diabetic or non-diabetic patient (all claimed). Also useful for the treatment of myocardial infarction, acute coronary syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarct and morbidity after stroke.

ADVANTAGE - The GLP-1 agonists are in the form of stable derivatives and exhibit a protracted profile of action compared to the corresponding other GLP-1 analogs. The GLP-1 analogs lower the brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in addition to lowering blood glucose and plasma lipids.

Dwg.0/1

L69 ANSWER 7 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 2000-514584 [46] WPIDS

CROSS REFERENCE: 2000-490999 [43]; 2001-514422 [56]; 2004-042706 [04]

DOC. NO. CPI: C2000-153464

TITLE: New formulations comprising an exendin or exendin agonist peptide used for increasing the sensitivity of a subject to insulin to treat diabetes.

DERWENT CLASS: A96 B04

INVENTOR(S): KOLTERMAN, O; LITALIEN, J J; YOUNG, A; L'ITALIEN, J J; KOLTERMAN, O G; YOUNG, A A

PATENT ASSIGNEE(S): (AMYL-N) AMYLIN PHARM INC; (KOLT-I) KOLTERMAN O G; (YOUN-I) YOUNG A A

COUNTRY COUNT: 91

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000041546	A2	20000720	(200046)*	EN	281
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000035819	A	20000801	(200054)		
NO 2001003468	A	20010914	(200163)		

EP 1140145 A2 20011010 (200167) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
BR 2000007820 A 20011120 (200202)
JP 2002534450 W 20021015 (200282) 211
CN 1384755 A 20021211 (200324)
US 2003087820 A1 20030508 (200337)

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2000041546	A2		WO 2000-US902	20000114
AU 2000035819	A		AU 2000-35819	20000114
NO 2001003468	A		WO 2000-US902	20000114
			NO 2001-3468	20010712
EP 1140145	A2		EP 2000-914425	20000114
			WO 2000-US902	20000114
BR 2000007820	A		BR 2000-7820	20000114
			WO 2000-US902	20000114
JP 2002534450	W		JP 2000-593167	20000114
			WO 2000-US902	20000114
CN 1384755	A		CN 2000-804847	20000114
US 2003087820	A1	Provisional	US 1999-116380P	19990114
		Provisional	US 2000-175365P	20000110
		CIP of	WO 2000-US902	20000114
		CIP of	US 2001-889330	20011227
			US 2002-157224	20020528

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000035819	A	Based on	WO 2000041546
EP 1140145	A2	Based on	WO 2000041546
BR 2000007820	A	Based on	WO 2000041546
JP 2002534450	W	Based on	WO 2000041546

PRIORITY APPLN. INFO: US 2000-175365P 20000110; US 1999-116380P 19990114; US 2001-889330 20011227; US 2002-157224 20020528

AN 2000-514584 [46] WPIDS
CR 2000-490999 [43]; 2001-514422 [56]; 2004-042706 [04]
AB WO 200041546 A UPAB: 20040115
NOVELTY - New formulation (I) comprising an exendin or exendin agonist peptide, a **buffer** and an iso-**osmolality** modifier has a pH of 3-7.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a solid or dry powder formulation (II) comprising 1-100% (w/w) of an exendin or exendin agonist peptide and for less that 100% exendin, a bulking agent.

ACTIVITY - Antidiabetic.

Fourteen subjects with type 2 diabetes were treated with diet and oral hypoglycemic agents and studied following withdrawal of oral agents for 10-14 days. Assessments were made following randomized, subcutaneous injection of placebo, 0.01, 0.02, 0.05 and 0.1 micro g/kg exendin-4 on separate days following an overnight fast. Injections were given immediately before a standardized Sustacal(RTM) meal 97kcal/kg) followed by collection of plasma glucose samples at frequent intervals during the subsequent 300 minutes. The glycemic response was measured as the time-weighted mean change in plasma concentration during the 5 hour period. The response ranged from a +42.0 plus or minus 7.9 mg/dl increment above the fasting glucose concentration for placebo compared a 30.5 plus or minus 8.6 mg/dl decrement below the fasting glucose concentration with 0.1 micro g/kg exendin-4.

MECHANISM OF ACTION - None given.

USE - The exendin or exendin agonist is used to increase the sensitivity of a subject to insulin (claimed) to treat diabetes and disorders which would benefit from agents which lower plasma glucose levels and disorders which would benefit from agents that delay and/or slow gastric emptying or reducing food intake.

Dwg.0/18

L69 ANSWER 8 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 1999-540562 [45] WPIDS

CROSS REFERENCE: 1998-207039 [18]; 1998-239721 [21]; 1999-540500 [45]; 1999-540507 [45]; 1999-540561 [45]; 1999-550859 [46]; 1999-561858 [47]; 2000-072123 [06]; 2001-595691 [67]; 2003-852812 [79]

DOC. NO. CPI: C1999-157857

TITLE: New derivatives of glucagon-like peptide-1 and exendin containing lipophilic substituent, for treating diabetes and obesity.

DERWENT CLASS: B04 B05 D16

INVENTOR(S): HUUSFELDT, P O; KNUDSEN, L B; MADSEN, K; NIELSEN, P F; BJORN, S E; KAARSHOLM, N C; OLSEN, H B; PEDERSEN, F Z

PATENT ASSIGNEE(S): (NOVO) NOVO-NORDISK AS; (NOVO) NOVO NORDISK AS; (HUUS-I) HUUSFELDT P O; (KNUD-I) KNUDSEN L B; (MADS-I) MADSEN K; (NIEL-I) NIELSEN P F

COUNTRY COUNT: 86

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9943708	A1	19990902	(199945)*	EN	69
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
ZA 9901571	A	19991124	(200001)		64
AU 9932477	A	19990915	(200004)		
EP 1056775	A1	20001206	(200064)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE					
US 6268343	B1	20010731	(200146)		
US 2001047084	A1	20011129	(200202)		
JP 2003522099	W	20030722	(200350)		91

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9943708	A1		WO 1999-DK86	19990225
ZA 9901571	A		ZA 1999-1571	19990226
AU 9932477	A		AU 1999-32477	19990225
EP 1056775	A1		EP 1999-936077	19990225
			WO 1999-DK86	19990225
US 6268343	B1	Provisional	US 1997-35904P	19970124
		Provisional	US 1997-36255P	19970124
		Provisional	US 1997-36226P	19970125
		CIP of	WO 1997-DK340	19970822
		CIP of	US 1997-918810	19970826
		CIP of	US 1998-38432	19980311
		Provisional	US 1998-82478P	19980421
		Provisional	US 1998-82480P	19980421
		Provisional	US 1998-82802P	19980423
		Provisional	US 1998-84357P	19980505
			US 1999-258750	19990226
US 2001047084	A1	Provisional	US 1998-84357P	19980505
		Cont of	WO 1999-DK86	19990224

		Cont of	US 1999-312177	19990514
			US 2001-886311	20010621
JP 2003522099	W		WO 1999-DK86	19990225
			JP 2000-533458	19990225

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9932477	A Based on	WO 9943708
EP 1056775	A1 Based on	WO 9943708
US 6268343	B1	WO 9808871
		WO 9943341
		WO 9943707
		WO 9943708
JP 2003522099	W Based on	WO 9943708

PRIORITY APPLN. INFO: US 1998-84357P 19980505; DK
1998-274 19980227; DK
1996-931 19960830; DK
1996-1259 19961108; DK
1996-1470 19961220; DK
1998-263 19980227; DK
1998-264 19980227; DK
1998-268 19980227; DK
1998-272 19980227; DK
1998-508 19980408; DK
1998-509 19980408

AN 1999-540562 [45] WPIDS

CR 1998-207039 [18]; 1998-239721 [21]; 1999-540500 [45]; 1999-540507 [45]; 1999-540561 [45]; 1999-550859 [46]; 1999-561858 [47]; 2000-072123 [06]; 2001-595691 [67]; 2003-852812 [79]

AB WO 9943708 A UPAB: 20031208

NOVELTY - Derivatives (A1) of GLP-1 (glucagon-like peptide-1) are new.

DETAILED DESCRIPTION - Derivatives (A1) of GLP-1 (glucagon-like peptide-1) (7-c) (with c = 35 or 36) having just one lipophilic substituent (LS) attached to the C-terminal amino acid (aa) and derivatives (A2) of exendin with LS attached to at least one aa of the parent peptide. A1 excludes compounds Arg26, Arg34, Lys36-(N epsilon (omega -carboxyX)-GLP-1(7-36)-OH

X = nonadecanoyl, heptadecanoyl, undecanoyl or heptanoyl.

An INDEPENDENT CLAIM is also included for compositions containing A1 and A2 plus a vehicle or carrier.

ACTIVITY - Antidiabetic; anti-obesity; insulinotropic; hypoglycemic.

MECHANISM OF ACTION - A1 stimulate secretion of insulin but suppress that of glucagon. They also inhibit gastric emptying and pancreatic secretion and may reduce food intake.

USE - A1 and A2 are used to treat (non-)insulin-dependent diabetes mellitus and obesity, and also to prevent hyperglycemia.

ADVANTAGE - A1 and A2 have a greater persistance in vivo than corresponding peptides without LS (because of reduced sensitivity to dipeptidyl peptidases). When formulated with other antidiabetic agents, they often produce a synergistic effect.

Dwg.0/0

=>